Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,099 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bioavailability Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults

NCT04083716
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H2158 Reference Formulation, ABI-H2158 Test Formulation
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

NCT06336096
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

NCT01072162
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone

NCT07046975
View directory record Official record
Conditions
Bioavailability Heathy Volunteers
Interventions
Torsemide and Spironolactone tablet, Torsemide Tablets and Spironolactone Tablets
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

NCT07563894
View directory record Official record
Conditions
Healthy
Interventions
PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants

NCT06571266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Anaheim, California • Los Alamitos, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2940680 in Healthy Participants

NCT01681186
View directory record Official record
Conditions
Healthy Participants
Interventions
LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), Lansoprazole, Placebo Capsule(s)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

NCT04992442
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-935 Oral Tablet, [14C]TAK-935 IV Infusion, [14C]TAK-935 Oral Solution
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 27, 2026, 11:00 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Bioavailability of Ration Items Containing Tart Cherry Extract

NCT07063173
View directory record Official record
Conditions
Bioavailability
Interventions
Fruit Bar, Powdered Drink, Commercially available 100% tart cherry juice, Placebo beverage
Dietary Supplement
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
17 Years to 39 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects

NCT01828827
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824 1000 mg
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of The Absolute Bioavailability of TH104

NCT06198686
View directory record Official record
Conditions
Healthy
Interventions
Nalmefene
Drug
Lead sponsor
Tharimmune Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers

NCT02877264
View directory record Official record
Conditions
Healthy
Interventions
vapendavir 132 mg capsule, vapendavir 264 mg tablet, vapendavir 24 mg/mL oral suspension
Drug
Lead sponsor
Aviragen Therapeutics
Industry
Eligibility
19 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants

NCT07341152
View directory record Official record
Conditions
Pain Management
Interventions
LTG-001 SDD, LTG-001 Formulation A Prototype 1, LTG-001 Formulation B prototype 2
Drug
Lead sponsor
Latigo Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 27, 2026, 11:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

NCT07540338
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
AL001, Lithium carbonate
Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Ixekizumab in Healthy Participants

NCT03848416
View directory record Official record
Conditions
Healthy
Interventions
Ixekizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

NCT05330858
View directory record Official record
Conditions
Pharmacokinetics
Interventions
ESK-001, Rabeprazole
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 27, 2026, 11:00 PM EDT
Active, not recruiting Phase 1 Interventional

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

NCT04800692
View directory record Official record
Conditions
Claudication, Intermittent, Peripheral Artery Disease, Peripheral Vascular Diseases
Interventions
Tetrahydrobiopterin 10 mg/kg, Tetrahydrobiopterin 20 mg/kg, L-Ascorbate, L-Arginine
Drug
Lead sponsor
Louis Messina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants

NCT05283681
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Grayslake, Illinois • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Lidocaine in Healthy Adults

NCT03310970
View directory record Official record
Conditions
Healthy
Interventions
Lidocaine 5% patch, Lidocaine hydrochloride, Lidoderm 5% patch
Drug
Lead sponsor
Nicole K Brogden
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions

NCT02138396
View directory record Official record
Conditions
Bioavailability
Interventions
Fentanyl Sublingual Spray (FSS), Fentanyl Citrate Injection (FCI), Naltrexone
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2014 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

NCT02359045
View directory record Official record
Conditions
Relative Bioavailability, AUC, Cmax, Pharmacokinetics
Interventions
D1400147, D14000136, D14000137, Epanova®
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of GSK1265744 Formulations

NCT01648257
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Hepatitis
Interventions
GSK1265744 Na Salt Tablets, GSK1265744 Free Acid Nanomilled Capsules, GSK1265744 Free Acid Micronized Capsules
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

NCT05730842
View directory record Official record
Conditions
Healthy Volunteer, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn
Interventions
EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension, Radiolabeled EDG-5506 Intravenous
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 27, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

NCT05767905
View directory record Official record
Conditions
Healthy
Interventions
PF-06821497 Treatment A, PF-06821497 Treatment B, PF-06821497 Treatment C, PF-06821497 Treatment D, PF-06821497 Treatment E, PF-06821497 Treatment F
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 27, 2026, 11:00 PM EDT